Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Opicapone and Controlled-Release Levodopa/Benserazide
NCT02169466Phase 1Completed
- Sponsor
- BIAL
- Start
- Jan 2009
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum Observed Plasma Concentration of Levodopa at 72 hours, Area Under the Plasma Concentration-time Curve from Time Zero to Last Quantifiable Concentration at 72 hours and 2 more. Started Jan 2009; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02169466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169466.